MolMed acute leukaemias: Contribution of TK presented at the BMT Tandem ... GroundReport MolMed S.p.A. (MLM.MI) announces the results of the contribution given by its investigational cell-based therapy TK to the treatment of haematologic malignancies through bone marrow transplantation from partially matched donors, presented at the Blood ... |
